Global Anticancer Drugs Market Size, by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy), by Indication (Lung Cancer, Colorectal Cancer, Breast Cancer) & Region - Key Manufacturers, Analysis, Growth Trends, and Forecast till 2026

  • Category : Healthcare and Pharma
  • |
  • ID : 1012239
  • |
  • Publishe Date : May 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Anticancer Drugs market was estimated to be valued at USD XX million in 2019 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Increase in prevalence of cancer worldwide, and rise in number of pipeline products are factors augmenting the anticancer drugs market globally. However, adverse effects and high costs associated with the use of cancer drugs are some of the major factors impeding the growth of the market.

The global anticancer drugs market is primarily segmented based on different drug class type, indication and regions.

On the basis of drug class type, the market is split into:
* Chemotherapy
* Targeted Therapy
* Immunotherapy (Biologic Therapy)
* Hormonal Therapy

On the basis of indication, the market is split into:
* Lung Cancer
* Stomach Cancer
* Colorectal Cancer
* Breast Cancer
* Prostate Cancer
* Other Cancers

Moreover, the market is classified based on regions and countries as follows:
* North America- U.S., Canada
* Europe- U.K., France, Germany, Italy and Rest of Europe
* Asia-Pacific- China, Japan, India and Rest of Asia Pacific
* South America- Brazil, Mexico and Rest of South America
* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players:
The key players profiled in the market include:
* AbbVie Inc.
* Astellas Pharma Inc.
* AstraZeneca PLC
* Bristol-Myers Squibb Company
* Celgene Corporation
* F. Hoffmann-La Roche ltd.
* Johnson & Johnson
* Merck & Co., Inc.
* Novartis AG
* Pfizer Inc.

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:
* Global, regional, country, drug class type, and indication market size and their forecast from 2015-2026
* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market
* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies
* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points
* Analysis on key players’ strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market
* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors’ short term and long term strategies
* Detailed insights on emerging regions, drug class type, and indication with qualitative and quantitative information and facts

Target Audience:
* Anticancer Drugs Manufacturers
* Traders, Importers, and Exporters
* Raw Material Suppliers and Distributors
* Research and Consulting Firms
* Government and Research Organizations
* Associations and Industry Bodies

Research Methodology:
The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:
* Manufacturers
* Suppliers
* Distributors
* Government Body & Associations
* Research Institutes

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Global Anticancer Drugs Market Overview
4.1. Market Segmentation & Scope
4.2. Market Trends
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Supply Chain Analysis
4.3. Global Anticancer Drugs Market - Porter\'s Five Forces Analysis
4.4. Global Anticancer Drugs Market - PESTEL Analysis

5. Global Anticancer Drugs Market, by Drug Class Type
5.1. Global Anticancer Drugs Market, Size and Forecast, 2015-2026
5.2. Global Anticancer Drugs Market, by Chemotherapy, 2015-2026
5.2.1. Key driving factors, trends and opportunities
5.2.2. Market size and forecast, 2015-2026
5.3. Global Anticancer Drugs Market, by Targeted Therapy, 2015-2026
5.3.1. Key driving factors, trends and opportunities
5.3.2. Market size and forecast, 2015-2026
5.4. Global Anticancer Drugs Market, by Immunotherapy, 2015-2026
5.4.1. Key driving factors, trends and opportunities
5.4.2. Market size and forecast, 2015-2026
5.5. Global Anticancer Drugs Market, by Hormonal Therapy, 2015-2026
5.5.1. Key driving factors, trends and opportunities
5.5.2. Market size and forecast, 2015-2026

6. Global Anticancer Drugs Market, by Indication
6.1. Global Anticancer Drugs Market, Size and Forecast, 2015-2026
6.2. Global Anticancer Drugs Market, for Lung Cancer, 2015-2026
6.2.1. Key driving factors, trends and opportunities
6.2.2. Market size and forecast, 2015-2026
6.3. Global Anticancer Drugs Market, for Stomach Cancer, 2015-2026
6.3.1. Key driving factors, trends and opportunities
6.3.2. Market size and forecast, 2015-2026
6.4. Global Anticancer Drugs Market, for Colorectal Cancer, 2015-2026
6.4.1. Key driving factors, trends and opportunities
6.4.2. Market size and forecast, 2015-2026
6.5. Global Anticancer Drugs Market, for Breast Cancer, 2015-2026
6.5.1. Key driving factors, trends and opportunities
6.5.2. Market size and forecast, 2015-2026
6.6. Global Anticancer Drugs Market, for Prostate Cancer, 2015-2026
6.6.1. Key driving factors, trends and opportunities
6.6.2. Market size and forecast, 2015-2026
6.7. Global Anticancer Drugs Market, for Other Cancers, 2015-2026
6.7.1. Key driving factors, trends and opportunities
6.7.2. Market size and forecast, 2015-2026

7. Global Anticancer Drugs Market, by Region
7.1. Anticancer Drugs Market Regional Analysis, 2015-2026
7.2. Global Anticancer Drugs Market Revenue (USD Million) by Region, 2015-2026
7.3. North America Anticancer Drugs Market, 2015-2026
7.3.1. North America Anticancer Drugs Market Size and Forecast, 2015-2026
7.3.2. North America Anticancer Drugs Market by Country, 2015-2026
7.3.2.1. U.S. Anticancer Drugs Market, 2015-2026
7.3.2.2. Canada Anticancer Drugs Market, 2015-2026
7.4. Europe Anticancer Drugs Market, 2015-2026
7.4.1. Europe Anticancer Drugs Market Size and Forecast, 2015-2026
7.4.2. Europe Anticancer Drugs Market by Country, 2015-2026
7.4.2.1. Germany Anticancer Drugs Market, 2015-2026
7.4.2.2. France Anticancer Drugs Market, 2015-2026
7.4.2.3. Italy Anticancer Drugs Market, 2015-2026
7.4.2.4. UK Anticancer Drugs Market, 2015-2026
7.4.2.5. Spain Anticancer Drugs Market, 2015-2026
7.4.2.6. Rest of Europe Anticancer Drugs Market, 2015-2026
7.5. Asia Pacific Anticancer Drugs Market, 2015-2026
7.5.1. Asia Pacific Anticancer Drugs Market Size and Forecast, 2015-2026
7.5.2. Asia Pacific Anticancer Drugs Market by Country, 2015-2026
7.5.2.1. Japan Anticancer Drugs Market, 2015-2026
7.5.2.2. China Anticancer Drugs Market, 2015-2026
7.5.2.3. India Anticancer Drugs Market, 2015-2026
7.5.2.4. Rest of Asia Pacific Anticancer Drugs Market, 2015-2026
7.6. South America Anticancer Drugs Market, 2015-2026
7.6.1. South America Anticancer Drugs Market Size and Forecast, 2015-2026
7.6.2. South America Anticancer Drugs Market by Country, 2015-2026
7.6.2.1. Mexico Anticancer Drugs Market, 2015-2026
7.6.2.2. Brazil Anticancer Drugs Market, 2015-2026
7.6.2.3. Rest of South America Anticancer Drugs Market, 2015-2026
7.7. Middle East & Africa Anticancer Drugs Market, 2015-2026
7.7.1. Middle East & Africa Anticancer Drugs Market Size and Forecast, 2015-2026
7.7.2. Middle East & Africa Anticancer Drugs Market by Country, 2015-2026
7.7.2.1. Saudi Arabia Anticancer Drugs Market, 2015-2026
7.7.2.2. South Africa Anticancer Drugs Market, 2015-2026
7.7.2.3. Rest of Middle East & Africa Anticancer Drugs Market, 2015-2026

8. Competitive Landscape
8.1. Introduction
8.2. Market Share Analysis/Top Player Positioning, 2019

9. Company Profiles
9.1. AbbVie Inc.
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Product Benchmarking
9.1.4. Key Developments
9.2. Astellas Pharma Inc.
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Product Benchmarking
9.2.4. Key Developments
9.3. AstraZeneca PLC
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Product Benchmarking
9.3.4. Key Developments
9.4. Bristol-Myers Squibb Company
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Product Benchmarking
9.4.4. Key Developments
9.5. Celgene Corporation
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Product Benchmarking
9.5.4. Key Developments
9.6. F. Hoffmann-La Roche Ltd.
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Product Benchmarking
9.6.4. Key Developments
9.7. Johnson & Johnson
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Product Benchmarking
9.7.4. Key Developments
9.8. Merck & Co., Inc.
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Product Benchmarking
9.8.4. Key Developments
9.9. Novartis AG
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Product Benchmarking
9.9.4. Key Developments
9.10. Pfizer Inc.
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Product Benchmarking
9.10.4. Key Developments

10. Key Insights



Content are not available

Choose License Type